Dry eye disease is one of the most underdiagnosed and undertreated conditions in Australian eye care. With the right technology, optometrists and ophthalmologists can move beyond drops and deliver in-clinic solutions patients are actively seeking.

Dry Eye disease is a chronic condition that affects millions of Australians. 85% of Dry Eye is caused by Meibomian Gland Dysfunction (MGD), and is a major cause of ocular discomfort. 

In Australia, 77% have experienced dry eye symptoms, yet many do not have a clear understanding of the signs, symptoms or causes.

Envision by InMode is the new in-office standard, revolutionising ocular care procedures for the treatment of meibomian gland dysfunction and the symptoms of dry eyes. This comprehensive, non-surgical ophthalmic device, deploys multiple programmable modalities which work synergistically to deliver precision ocular treatments.

Envision’s small-size applicators and precise depth control allow for safe and highly efficacious procedures in the small, delicate subdermal layers of the periorbital region. With Envision, practitioners deliver cutting edge technologies to improve patient vision and quality of life.

With a structured treatment protocol and repeat-visit care pathway, Envision supports a recurring revenue model alongside your existing clinical income. 

Set your practice apart and introduce a new revenue stream by becoming a holistic Thermal RF, IPL and Morpheus8 RF microneedling.

Patients receive customized, non-surgical, energy-based therapies for the face and periorbital region that are safe, effective and comfortable.

Two government-backed tax incentives are available to eligible Australian medical practices right now. Here's what they are and how they apply to a technology investment before EOFY.

An optometry practice operating as a company has had two profitable years and has identified significant unmet dry eye treatment demand in its existing patient base. Before 30 June, it invests in the Envision platform and purchases supplementary accessories separately — under $20,000.

The accessories are immediately written off. The platform investment generates a company tax loss that — for eligible companies — can be carried back against prior tax paid, generating a potential cash refund. Envision begins delivering structured, multi-session dry eye treatment programs — creating a new, recurring revenue stream from patients who previously received no clinical intervention.

Speak with an InMode Australia specialist about EOFY investment options. We'll walk you through what's possible — your accountant can confirm what applies to your practice structure.

For any Optometrist or Ophthalmologist who wants to differentiate themselves in an increasingly competitive market, InMode's training and support programme is a point of difference — not a checkbox after purchase.

Learn more about how Envision can drive your practice’s financial health, broaden your patient base, and solidify your position as a leader in precision tissue treatments.

© 2026 InMode

Privacy Policy